与尿路感染相关的治疗与膀胱癌诊断延迟相关:一项全国性人群研究
基于BladderBaSe 2.0数据,比较29921例膀胱癌患者与149467例匹配对照在诊断前3年内因尿路感染接受治疗的情况。至少一次尿路感染治疗与更晚期疾病风险相关,男性OR 1.28(95%CI 1.19-1.37),女性OR 1.42(95%CI 1.27-1.58),且风险随治疗次数增加而升高。作者认为需进一步研究以明确膀胱癌诊断路径中可能延迟的原因。
要点
- 膀胱癌患者诊断前因尿路感染接受治疗的比例高于匹配对照人群。
- 至少一次尿路感染治疗与更晚期膀胱癌风险相关,男性OR 1.28(95%CI 1.19-1.37),女性OR 1.42(95%CI 1.27-1.58)。
- 更晚期疾病风险随尿路感染治疗次数增加而升高,两性均如此。
核心结论
- 膀胱癌患者诊断前因尿路感染接受抗生素治疗与诊断时更晚期疾病相关。
- 需进一步研究结合其他因素以明确膀胱癌诊断路径中可能延迟的原因。
研究设计与样本
- 使用BladderBaSe 2.0数据,纳入2008-2019年诊断的膀胱癌患者,并与匹配对照人群比较诊断前3年内与尿路感染相关的治疗。
- 在膀胱癌队列中分析尿路感染治疗与诊断时更晚期疾病之间的关联,采用广义有序逻辑回归计算更晚期疾病(按非肌层浸润性膀胱癌、肌层浸润性膀胱癌、转移性膀胱癌排序)的比值比(OR)。
- 研究人群包括29921例膀胱癌患者和149467例匹配对照。
主要发现
- 接受尿路感染治疗的个体比例在患者组中高于对应的对照组,在肌层浸润性膀胱癌和转移性膀胱癌亚组中差异最大。
- 至少一次尿路感染治疗 versus 无治疗与更晚期疾病(肌层浸润性膀胱癌或转移性膀胱癌)风险的OR为男性1.28(95%CI 1.19-1.37),女性1.42(95%CI 1.27-1.58)。
- 更晚期疾病风险随尿路感染治疗次数增加而升高,两性均如此。
局限性
- 需进一步研究结合其他因素以明确膀胱癌诊断路径中可能延迟的原因。
- 需进一步研究以明确膀胱癌诊断中可能延迟的原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: It has been suggested that urinary tract infections (UTIs) are associated with delayed diagnosis of bladder cancer (BC). Our aim was to investigate prediagnostic treatments related to UTI and the relation to BC diagnostic delay, reflected by advanced disease at diagnosis. METHODS: We used data from the BladderBaSe 2.0 with data of treatments related to UTI up to 3 yr before BC diagnosis (2008-2019) for BC patients in comparison to a matched reference population. We investigated the association between UTI treatments and more advanced disease at diagnosis in the BC cohort. We used generalized ordered logistic regression to calculate odds ratios (ORs) for more advanced disease as an ordered outcome: non-muscle-invasive BC (NMIBC), muscle-invasive BC (MIBC), and metastatic BC (MBC). KEY FINDINGS AND LIMITATIONS: The study population included 29 921 BC patients and 149 467 matched reference subjects. The proportions of individuals receiving UTI treatment were higher in the patient groups than in the corresponding reference groups, with the greatest differences observed for the MIBC and MBC subgroups. The OR for the risk of more advanced disease (MIBC or MBC) with at least one UTI treatment versus none was 1.28 (95% confidence interval [CI] 1.19-1.37) for men and 1.42 (95 % CI 1.27-1.58) for women. The association to risk of more advanced disease increased with the number of UTI treatments for both sexes. CONCLUSIONS AND CLINICAL IMPLICATIONS: Further studies on the effects of treatments related to UTI in combination with other factors are needed to identify reasons for possible delays in the BC diagnostic pathway. PATIENT SUMMARY: We found that for patients with bladder cancer, previous antibiotic treatment for a urinary tract infection was linked to more advanced disease at diagnosis. Further studies are needed to identify reasons for possible delays in the diagnosis of bladder cancer.
引用
- Liedberg F, Gårdmark T, Hagberg O, et al. Treatment Related to Urinary Tract Infections Is Associated with Delayed Diagnosis of Urinary Bladder Cancer: A Nationwide Population-based Study. Eur Urol Oncol. 2024. PMID: 39143001. doi:10.1016/j.euo.2024.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。